Effects of aspirin on serum C-reactive protein and interleukin-6 levels in patients with type 2 diabetes without cardiovascular disease: a randomized placebo-controlled crossover trial
| Autor: | Jouke T. Tamsma, Menno V. Huisman, Marcel M. C. Hovens, Y. Groeneveld, Marijke Frölich, J. D. Snoep |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
medicine.medical_specialty Endocrinology Diabetes and Metabolism Type 2 diabetes Placebo Gastroenterology law.invention Endocrinology Randomized controlled trial law Internal medicine Diabetes mellitus Antithrombotic Internal Medicine medicine Humans Prospective Studies Aspirin Cross-Over Studies biology Interleukin-6 business.industry C-reactive protein Middle Aged Atherosclerosis medicine.disease Crossover study C-Reactive Protein Treatment Outcome Diabetes Mellitus Type 2 biology.protein Female business Diabetic Angiopathies Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | Diabetes, Obesity and Metabolism. 10:668-674 |
| ISSN: | 1463-1326 1462-8902 |
| DOI: | 10.1111/j.1463-1326.2007.00794.x |
| Popis: | Aim: Low-grade inflammation plays a pivotal role in atherogenesis in type 2 diabetes. Next to its antithrombotic effects, several lines of evidence demonstrate anti-inflammatory properties of aspirin. We determined the effects of aspirin on inflammation – represented by C-reactive protein (CRP) and interleukin-6 (IL-6) – in type 2 diabetic subjects without cardiovascular disease and assessed differential effects of aspirin 300 mg compared with 100 mg. Methods: A randomized, placebo-controlled, double-blind, crossover trial was performed in 40 type 2 diabetic patients. In two periods of 6 weeks, patients used 100 or 300 mg aspirin and placebo. Plasma CRP and IL-6 levels were measured before and after both periods. Results: Use of aspirin resulted in a CRP reduction of 1.23 ± 1.02 mg/l (mean ± s.e.m.), whereas use of placebo resulted in a mean increase of 0.04 ± 1.32 mg/l (P = 0.366). Aspirin reduced IL-6 with 0.7 ± 0.5 pg/ml, whereas use of placebo resulted in a mean increase of 0.2 ± 0.8 pg/ml (P = 0.302). There were no significant differences in effects on CRP and IL-6 between 100 and 300 mg aspirin. Conclusions: Our results indicate that a 6-week course of aspirin does not improve low-grade inflammation in patients with type 2 diabetes without cardiovascular disease, although a modest effect could not be excluded. No significant differential effects between aspirin 100 and 300 mg were found. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text